Abstract YO19
Case summary
Recent studies have shown evidence of cross-lineage transdifferentiation of B-cell lymphomas, such as low-grade FL and CLL/SLL,to histiocytic and dendritic cell sarcomas, but the clonal relationship between the 2 neoplasms is still unclear. Here, we report the morphologic, molecular and cytogenetic analysis of a unique case of CLL/SLL associated with indeterminate dendritic cell tumor and possibly a hybrid lymphodendritic cell neoplasm , using immunohistochemistry, electron microscopy, in situ hybridization and FISH.A 48-year-old Chinese female presented with left upper neck swelling. Blood examination revealed lymphocytosis.Microscopic examinations showed the lymph node has effaced architecture, and has a very complicated, variegated appearance with three distinct components. The first component contained small lymphocytes, prolymphocytes and paraimmunoblasts, showing typical CLL/SLL immunophenotype, with ZAP-70 positive and EBV negative. The second component contained nodular aggregates of large pink cells with abundant eosinophilic cytoplasm and deeply grooved nuclei, showing immunophenotype of indeterminate dendritic cell tumor and EBV positive. The third component had intermediate morphologic features between lymphoid cells and dendritic cells characteristics, a bit reminiscent of anaplastic large cell lymphoma, but expressed some B cell markers PAX5 and OCT2, as well as dendritic/histiocytic markers CD1a, CD68, Fascin, and Lysozyme, and was diffusely EBV positive. Electron microscopy revealed the cells in the third component had short and thick bulges like dendritic cell. FISH analysis using CLL probes showed identical deletion 17p13.1, deletion 11q22.3, and deletion 13q14.3 in all 3 components. Sharing of CD5 and OCT2 expression and identical cytogenetic abnormality in all 3 components suggest a common clonal origin for the three components.Our study provides evidence for transdifferentiation of CLL/SLL to dendritic cell tumor possibly via the intermediate linklymplymphodendritic cell neoplasm, and suggests that EBV may play a role in this phenomenon.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract
508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
Presenter: Jinliang Wang
Session: Poster display session
Resources:
Abstract
525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma
Presenter: Akito Fukuda
Session: Poster display session
Resources:
Abstract
524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
Presenter: Heekyung Ahn
Session: Poster display session
Resources:
Abstract
513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed
Presenter: Shingo Kitagawa
Session: Poster display session
Resources:
Abstract
493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
Presenter: Sarita Shrivastva
Session: Poster display session
Resources:
Abstract
494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract